Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials / Denise Battaglini, Chiara Robba, Paolo Pelosi, Patricia R.M. Rocco
ABSTRACT Introduction Ventilatory management and general supportive care of acute respiratory distress syndrome (ARDS) in the adult population have led to significant clinical improvements, but morbidity and mortality remain high. Pharmacologic strategies acting on the coagulation cascade, inflammation, oxidative stress, and endothelial cell injury have been targeted in the last decade for patients with ARDS, but only a few of these have shown potential benefits with a meaningful clinical response and improved patient outcomes. The lack of availability of specific pharmacologic treatments for ARDS can be attributed to its complex pathophysiology, different risk factors, huge heterogeneity, and difficult classification into specific biological phenotypes and genotypes. Areas covered In this narrative review, we briefly discuss the relevance and current advances in pharmacologic treatments for ARDS in adults and the need for the development of new pharmacological strategies. Expert opinion Identification of ARDS phenotypes, risk factors, heterogeneity, and pathophysiology may help to design clinical trials personalized according to ARDS-specific features, thus hopefully decreasing the rate of failed clinical pharmacologic trials. This concept is still under clinical investigation and needs further development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 27(2022), 2, Seite 187-209 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Battaglini, Denise [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Acute lung injury |
|---|
| Umfang: |
1 Online-Ressource (23 p) |
|---|
| doi: |
10.1080/14728214.2022.2105833 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011130768 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011130768 | ||
| 003 | DE-627 | ||
| 005 | 20230713210842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2022.2105833 |2 doi | |
| 035 | |a (DE-627)KFL011130768 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/14728214.2022.2105833 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Battaglini, Denise |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials |c Denise Battaglini, Chiara Robba, Paolo Pelosi, Patricia R.M. Rocco |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (23 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction Ventilatory management and general supportive care of acute respiratory distress syndrome (ARDS) in the adult population have led to significant clinical improvements, but morbidity and mortality remain high. Pharmacologic strategies acting on the coagulation cascade, inflammation, oxidative stress, and endothelial cell injury have been targeted in the last decade for patients with ARDS, but only a few of these have shown potential benefits with a meaningful clinical response and improved patient outcomes. The lack of availability of specific pharmacologic treatments for ARDS can be attributed to its complex pathophysiology, different risk factors, huge heterogeneity, and difficult classification into specific biological phenotypes and genotypes. Areas covered In this narrative review, we briefly discuss the relevance and current advances in pharmacologic treatments for ARDS in adults and the need for the development of new pharmacological strategies. Expert opinion Identification of ARDS phenotypes, risk factors, heterogeneity, and pathophysiology may help to design clinical trials personalized according to ARDS-specific features, thus hopefully decreasing the rate of failed clinical pharmacologic trials. This concept is still under clinical investigation and needs further development | ||
| 653 | |a Acute lung injury | ||
| 653 | |a acute respiratory distress syndrome | ||
| 653 | |a pharmacologic treatment | ||
| 653 | |a phenotypes | ||
| 653 | |a trials | ||
| 700 | 1 | |a Robba, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Pelosi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Rocco, Patricia R.M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 2001 |g 27(2022), 2, Seite 187-209 |h Online-Ressource |w (DE-627)KFL000006033 |w (DE-600)2030079-7 |w (DE-576)302969306 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:2 |g pages:187-209 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/14728214.2022.2105833 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_05 | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 2 |h 187-209 | ||